
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare demonstrated a resilient performance in 4Q24, with EBITDA growth exceeding 6% year-over-year when adjusted for state DPP impacts and hurricane effects, highlighting the company's operational strength. The organization reported a significant increase in same-store inpatient surgeries, with growth of 180 basis points year-over-year, indicating strong demand for its healthcare services. Furthermore, the firm's robust infrastructure and strategic positioning in attractive markets enhance its potential for continued market share gains, supported by a $400 million year-over-year rise in state supplemental payments for 2024, reflecting its strong financial fundamentals.
Bears say
HCA Healthcare faces significant financial headwinds heading into 2025, primarily due to anticipated declines in Medicaid direct payment programs and the non-repeat of supportive factors from prior periods, which are expected to negatively impact equivalent admissions growth. The company's adjusted EBITDA estimate has been slightly lowered to $14.58 billion, reflecting ongoing regulatory uncertainties and decreased expectations of growth in admissions. Moreover, the confluence of a higher-than-expected Medicaid increase and operational disruptions has created uncertainty regarding core operations, contributing to a negative outlook for the stock despite previous positive re-ratings.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares